Form 4 for AMGN Amgen

Accepted 2025-05-08 00:00:00 ET · period of report 2025-05-06 · accession 0001127602-25-013786 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2025-05-08	2025-05-06	AMGN	REESE DAVID M	EVP, CTO	A - Grant	$0.00	+3,549	42.1K	+9%	$0
D	2025-05-08	2025-05-06	AMGN	REESE DAVID M	EVP, CTO	A - Grant	$270.44	+22.9K	22.9K	New	+$6.20M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-05-06	A	A	3,549	$0.00	42,116	D	—	—	(F1) The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/6/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. (F2) These shares include 397 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
2	Derivative	Nqso (Right to Buy)	2025-05-06	A	A	22,944	$270.44	22,944	D	$270.44 · 2026-05-06 to 2035-05-06	22,944 Common Stock	(F3) These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/6/2026.